Working Document, September 2017
World's largest Science, Technology & Medicine Open Access book publisher
Chapter 7 from the book People's Movements in the 21st Century - Risks, Challenges and Benefits
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Treating children infected with intestinal worms is one of the simplest and most cost–effective ways to improve their health.
The recommendations are intended for a wide audience, including policy-makers and their expert advisers as well as technical and programme staff at government institution...s and organizations involved in the design, implementation and expansion of programmes to control soil-transmitted helminth infections.
more
PQDx 0159-055-00
WHO PQ Public Report
February/2017, version 5.0
3rd Edition – July 2017
www.msfaccess.org
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period 5-11 November 2017 and includes updates on measles, rubella, chikungunya, West Nile virus, Plague, monkeypox, legionnair...es's disease, influenza and Marburg virus disease.
more
A compendium of TB REACH case studies, lessons learned and a monitoring and evaluation framework.
Accessed November 2017.
РУКОВОДСТВО ДЛЯ АКТИВИСТОВ ПО ИНСТРУМЕНТАМ ДЛЯ ДИАГНОСТИКИ ТУБЕРКУЛЕЗА ЯНВАРЬ.
Lancet Planet Health 2017 Published Online November 6, 2017 http://dx.doi.org/10.1016/S2542-5196(17)30141-9
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more